Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia
Although the dopamine D2 receptor (DRD2) has been a main target of antipsychotic pharmacotherapy for the treatment of schizophrenia, the standard treatment does not offer sufficient relief of symptoms to 20%–30% of patients suffering from this disorder. Moreover, over 80% of patients experience rela...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
MDPI
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691170/ |